Announcements Trials
Browse Landscape

Phase

Phase 2 2Phase 1/2 1

Status

Terminated 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Sarcoma 1

Conditions

Carcinoma, Non-Small-Cell Lung 47Prostatic Neoplasms 33Breast Neoplasms 23Stomach Neoplasms 16Squamous Cell Carcinoma of Head and Neck 15Lung Neoplasms 15Esophageal Neoplasms 13Neoplasm Metastasis 11Sarcoma 9Neoplasms 9Colorectal Neoplasms 7Urinary Bladder Neoplasms 6Ovarian Neoplasms 6Head and Neck Neoplasms 6Carcinoma, Transitional Cell 6Carcinoma, Renal Cell 6Melanoma 5Uterine Cervical Neoplasms 4Triple Negative Breast Neoplasms 4Small Cell Lung Carcinoma 4Carcinoma, Ovarian Epithelial 4Breast Neoplasms, Male 4Salivary Gland Neoplasms 3Prostatic Neoplasms, Castration-Resistant 3Pancreatic Neoplasms 3Non-Muscle Invasive Bladder Neoplasms 3Leiomyosarcoma 3Inflammatory Breast Neoplasms 3Endometrial Neoplasms 3Carcinoma, Squamous Cell 3

Interventions

Cyclophosphamide 3Imatinib Mesylate 2temsirolimus 1tazemetostat 1sapanisertib 1pazopanib 1olaparib 1lutetium Lu 177 dotatate 1liposomal doxorubicin 1lentiviral minigene vaccine of COVID-19 coronavirus 1aldesleukin 1Zoledronic Acid 1Sunitinib 1Ramucirumab 1Nivolumab 1Methotrexate 1Leukapheresis 1Interleukin-2 1Injections 1Immunotherapy, Adoptive 1Ifosfamide 1HhAntag691 1Gemcitabine 1Everolimus 1Epirubicin 1Doxorubicin 1Docetaxel 1Decitabine 1Dacarbazine 1Cisplatin 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 1/2 × Sarcoma, Synovial × Docetaxel × Clear all
NCT04145700 2023-09-13

CAMPFIRE: A Study of Ramucirumab (LY3009806) in Children and Young Adults With Synovial Sarcoma

Eli Lilly and Company

Phase 1/2 Terminated
23 enrolled 15 charts
Sarcoma

Sarcoma, Sarcoma, Synovial

Data powered by HemOnc (CC BY 4.0) Colophon âš¡